Immune Design Corporation Reports Second Quarter 2017 Financial Results And Provides Corporate Update

SEATTLE and SOUTH SAN FRANCISCO, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today reported financial results and a corporate update for the second quarter ended June 30, 2017.

“During the second quarter, based on the positive data to date, Immune Design made the decision to move forward both of our lead product candidates, CMB305 and G100, and discuss regulatory paths for approval with the FDA,” said Carlos Paya, M.D., Ph.D., President and Chief Executive Officer of Immune Design.

Back to news